FOXO TECHNOLOGIES Stock Price, News & Analysis
Company Description
FOXO Technologies Inc. (FOXO) is a Delaware corporation whose common stock trades on the over-the-counter (OTC) market under the symbol FOXO. According to company disclosures, FOXO has transitioned into a diversified healthcare and life sciences platform, owning and operating subsidiaries in rural acute care, behavioral health, biospecimen sourcing, and biotechnology.
Business overview and operating subsidiaries
FOXO states that it owns and operates multiple healthcare-related businesses and a biotechnology subsidiary:
- Rennova Community Health, Inc. owns and operates Scott County Community Hospital, Inc., which does business as Big South Fork Medical Center, a critical access designated (CAH) hospital in East Tennessee.
- Myrtle Recovery Centers, Inc. operates a 30-bed behavioral health facility in East Tennessee. Myrtle provides inpatient services for medically supervised withdrawal (detox) and residential treatment, and outpatient services for medication-assisted treatment (MAT) and office-based opioid treatment (OBOT) programs.
- Vector BioSource, Inc. is described as an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries in the United States and abroad.
- FOXO Labs, Inc. is a biotechnology company focused on improving human health and life span through technology and product development, including an epigenetics business that uses DNA epigenetic data.
Through these subsidiaries, FOXO is involved in healthcare delivery in rural communities, behavioral health and substance use disorder treatment, biospecimen supply for research, and biotechnology and epigenetics.
Healthcare services: Big South Fork Medical Center
Scott County Community Hospital, doing business as Big South Fork Medical Center, is identified as FOXO’s flagship acute care hospital and is designated as a Critical Access Hospital serving Scott County, Tennessee and surrounding communities. The facility provides inpatient services, including swing bed services, outpatient services, and emergency room services, together with ancillary services such as laboratory, radiology, pharmacy and respiratory services.
The hospital has entered into a Performance Network Agreement with Covenant Health to participate in its performance network as a provider of swing bed services. FOXO highlights that Big South Fork Medical Center is positioned to provide post-acute swing bed care for patients who no longer meet acute care admission criteria but still require recovery support closer to their communities.
Behavioral health: Myrtle Recovery Centers
Myrtle Recovery Centers, Inc. operates an alcohol and drug residential treatment facility in Oneida, Tennessee. The company reports that Myrtle’s first location opened in August 2023 and provides:
- Residential treatment services for substance use disorders.
- Medically supervised withdrawal (detox) services.
- Outpatient services for MAT and OBOT programs.
FOXO notes that Myrtle’s Oneida facility has operated at or near full capacity, with a waiting list for admissions. Myrtle has received operating license renewals from the State of Tennessee’s Department of Mental Health and Substance Abuse Services following inspections. The company also reports that Myrtle has been approved to receive Scott County Opioid Abatement Funds to provide care for uninsured patients from Scott County at its Oneida location.
In its year-end shareholder review, FOXO describes Myrtle as having served patients from many counties in Tennessee and receiving local and statewide recognition and awards for community outreach and its care model. Myrtle is also working with software developers on a mobile application called “Evana” intended to connect post-discharge patients with Myrtle care professionals to support after-care and alumni engagement.
Biospecimen sourcing: Vector BioSource, Inc.
Vector BioSource, Inc. is described by FOXO as an information, data and biospecimen sourcing provider. Vector sources biospecimens, such as blood and urine, and sells these materials to biotechnology and pharmaceutical research sectors in the United States and abroad. FOXO reports that Vector generated net revenues in the second quarter of 2025 and that the business is expected to grow as capital is invested to build infrastructure, expand markets and secure proprietary sources of supply.
FOXO completed the acquisition of Vector BioSource Inc. through a stock purchase agreement, with Vector becoming a wholly owned subsidiary of FOXO Acquisition Corporation, a wholly owned subsidiary of FOXO Technologies Inc. The transaction consideration included cash, shares of FOXO’s Series E Cumulative Redeemable Secured Preferred Stock, and warrants to purchase FOXO Class A common stock.
Biotechnology and epigenetics: FOXO Labs, Inc.
FOXO Labs, Inc. is presented as a biotechnology subsidiary focused on improving human health and life span. The company’s epigenetics business is described as developing and integrating epigenetic biomarkers into underwriting protocols and consumer engagement tools. FOXO Labs owns U.S. Patent No. 11,817,214 titled “Machine Learning Model Trained to Determine a Biochemical State and/or Medical Condition Using DNA Epigenetic Data.”
According to FOXO, epigenetic technology can provide health, lifestyle and longevity insights from a saliva sample by using saliva-based epigenetic biomarkers, reducing the need for invasive blood and urine collection. FOXO Labs offers epigenetic testing services and bioinformatics tools to support research. The company also describes an AI-based personalized health and wellness coaching concept that uses wellness data from wearables together with epigenetic analyses to generate lifestyle guidance. FOXO has announced that its board approved pursuing a spin-off of FOXO Labs, Inc. as a separate entity, while retaining some ownership.
Corporate structure, capital and listing status
FOXO Technologies Inc. is incorporated in Delaware. The company has multiple series of preferred stock, including Series A, Series B, Series C, Series D and Series E preferred stock, with various rights and conversion terms described in its Certificates of Designation and subsequent amendments. Recent amendments have addressed conversion pricing, voting rights and dividend terms for these preferred series.
FOXO has disclosed that Rennova Health, Inc., which is controlled by the company’s CEO, has acted as a majority stockholder and has approved certain corporate actions by written consent, including increases in authorized shares of Class A common stock and preferred stock and the election of directors.
In 2025, FOXO’s board approved a reverse stock split of its Class A common stock at a ratio of 1-for-1.99, intended to support compliance with NYSE American continued listing requirements related to minimum share price. Subsequently, FOXO reported that NYSE Regulation commenced proceedings to delist FOXO’s Class A common stock from NYSE American due to the share price falling below the NYSE American minimum price threshold. Trading of FOXO’s common stock on NYSE American was suspended, and the company obtained confirmation from FINRA that its common stock could be quoted and traded on the OTC market under the symbol “FOXO.”
Growth and acquisition strategy
FOXO’s communications to shareholders emphasize a strategy of growing its healthcare and related businesses through both organic expansion and acquisitions. The company highlights:
- Expansion of Myrtle Recovery Centers’ operations and consideration of additional locations and acquisitions in behavioral health.
- Development of Big South Fork Medical Center’s services, including swing bed and wound care services and participation in a performance network agreement with Covenant Health for swing bed services.
- Growth initiatives at Vector BioSource, including funding to support its budget and expansion plans.
- Exploration of acquisition opportunities in assisted living and memory care, including a non-binding acquisition agreement for an assisted living and memory care facility in South Florida, and broader interest in assisted living and behavioral health sectors.
FOXO has also formed a wholly owned subsidiary, FOXO Acquisition Corporation (FAC), to serve as a vehicle for acquisitions and created a new series of preferred stock, Series E Cumulative Redeemable Secured Preferred Stock, which is secured by the equity of FAC and carries both cash and common stock dividends. The company has indicated an intention to seek a separate trading symbol for the Series E preferred stock, while noting that such a listing is not certain.
Regulatory reporting and governance
FOXO files reports with the U.S. Securities and Exchange Commission, including Current Reports on Form 8-K describing material events such as acquisitions, amendments to its Certificate of Incorporation and preferred stock designations, reverse stock split actions, and shareholder approvals via written consent. The company has disclosed the appointment of a Chief Financial Officer and the ratification of its independent registered public accounting firm by its majority stockholder on a non-binding basis.
FAQs about FOXO Technologies Inc. (FOXO)
The following questions and answers summarize key aspects of FOXO based on available company disclosures.
What does FOXO Technologies Inc. do?
FOXO Technologies Inc. owns and operates subsidiaries in healthcare services and biotechnology. These include a critical access hospital in East Tennessee, a behavioral health and substance use disorder treatment facility, a biospecimen sourcing business serving biotechnology and pharmaceutical research, and a biotechnology subsidiary focused on epigenetics and longevity-related technology.
What are FOXO’s main operating subsidiaries?
According to FOXO, its key subsidiaries are Rennova Community Health, Inc. (owner of Scott County Community Hospital, d/b/a Big South Fork Medical Center), Myrtle Recovery Centers, Inc., Vector BioSource, Inc., and FOXO Labs, Inc. Each subsidiary focuses on a distinct area: rural acute care, behavioral health, biospecimen sourcing, and biotechnology/epigenetics, respectively.
Where does FOXO provide healthcare services?
FOXO reports that its healthcare service operations are located in East Tennessee. Big South Fork Medical Center serves Scott County, Tennessee and surrounding communities as a critical access hospital, and Myrtle Recovery Centers operates an alcohol and drug residential treatment facility in Oneida, Tennessee.
What services are offered by Myrtle Recovery Centers, Inc.?
Myrtle Recovery Centers provides inpatient services for medically supervised withdrawal (detox) and residential treatment for substance use disorders, as well as outpatient services for medication-assisted treatment (MAT) and office-based opioid treatment (OBOT) programs. The facility in Oneida, Tennessee operates as an alcohol and drug residential treatment facility and has received license renewals from the State of Tennessee.
What is Big South Fork Medical Center?
Big South Fork Medical Center is the business name of Scott County Community Hospital, Inc., which is owned and operated by Rennova Community Health, Inc., a FOXO subsidiary. It is designated as a Critical Access Hospital and provides inpatient (including swing bed), outpatient and emergency room services, along with ancillary services such as laboratory, radiology, pharmacy and respiratory services.
What does Vector BioSource, Inc. do within FOXO?
Vector BioSource, Inc. is described as an information, data and biospecimen sourcing provider. It sources biospecimens, such as blood and urine, and sells them to biotechnology, clinical research and pharmaceutical research sectors in the U.S. and abroad. Following a stock purchase agreement and closing, Vector became a wholly owned subsidiary of FOXO Acquisition Corporation, which is wholly owned by FOXO Technologies Inc.
What is FOXO Labs, Inc. and its epigenetics business?
FOXO Labs, Inc. is a biotechnology subsidiary focused on improving human health and life span. Its epigenetics business develops and integrates epigenetic biomarkers into underwriting protocols and consumer engagement tools and holds a U.S. patent related to a machine learning model using DNA epigenetic data to determine biochemical states or medical conditions. FOXO Labs offers epigenetic testing services and bioinformatics tools and has described an AI-based personalized health and wellness coaching approach.
Has FOXO announced any corporate restructuring related to FOXO Labs?
FOXO has announced that its board of directors approved pursuing a spin-off of FOXO Labs, Inc., the subsidiary focused on epigenetics. The company has indicated that the intent is for FOXO shareholders to benefit from directly owning FOXO Labs, Inc., while FOXO Technologies Inc. retains some ownership, subject to completing the spin-off.
What is FOXO’s stock listing status?
FOXO has reported that its Class A common stock was subject to NYSE American listing requirements and that a reverse stock split was approved to help meet minimum price criteria. Subsequently, NYSE Regulation commenced proceedings to delist FOXO’s Class A common stock due to the share price falling below the NYSE American minimum threshold, and trading on NYSE American was suspended. FOXO has received confirmation that its common stock can be quoted and traded on the OTC market under the symbol “FOXO.”
How is FOXO changing its capital structure?
Through written consents of a majority stockholder, FOXO has approved increases in its authorized shares of Class A common stock and preferred stock, subject to board discretion on effective dates. The company has also amended designations for several series of preferred stock (Series A, B, C, D and E) to adjust conversion pricing, voting rights and dividend terms. These changes are documented in Certificates of Amendment and Amended and Restated Certificates of Designation filed with the Delaware Secretary of State and reported on Forms 8-K.
What is FOXO Acquisition Corporation (FAC)?
FOXO has formed FOXO Acquisition Corporation (FAC) as a wholly owned subsidiary intended to serve as a vehicle for acquisitions. Vector BioSource, Inc. is held as a wholly owned subsidiary of FAC. The company’s Series E Cumulative Redeemable Secured Preferred Stock is secured by the equity of FAC, and FOXO has used Series E preferred stock as part of the consideration in the Vector acquisition.